Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age

Trial Profile

Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Bacterial meningitis; Meningococcal infections; Meningococcal meningitis
  • Focus Pharmacodynamics
  • Acronyms MENACWY CONJ-032_V59_71
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Feb 2019 Status changed from recruiting to active, no longer recruiting.
    • 17 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 28 Aug 2018 Status changed to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top